10x Genomics, Inc. is maintaining its full year 2022 revenue guidance of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.59 USD | +2.57% | -1.25% | -50.70% |
Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.70% | 3.29B | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B | |
-5.02% | 1.64B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Maintains Revenue Guidance for Full Year 2022